We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
- Authors
Herbst, Roy S; Prager, Diane; Hermann, Robert; Fehrenbacher, Lou; Johnson, Bruce E; Sandler, Alan; Kris, Mark G; Tran, Hai T; Klein, Pam; Li, Xin; Ramies, David; Johnson, David H; Miller, Vincent A; TRIBUTE Investigator Group
- Abstract
Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non-small-cell lung cancer (NSCLC). Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Vol 23, Issue 25, p5892
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.02.840